JPRN-jRCT2041230099招募中2 期
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis - Clairleaf
Kutsunai Mitsuru0 个研究点目标入组 220 人开始时间: 2023年10月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients who completed the treatment period in Phase II trial (1397-0012) as planned
- •per protocol.
- •2. Male or female patients.
- •Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the patient information.
- •3. Signed and dated written informed consent prior to admission to the trial, in accordance with Good Clinical Practice (GCP) and local legislation.
排除标准
- •1. Moderate or severe liver disease (defined by Child-Pugh score B or C hepatic impairment) or AST and/or ALT >3.0x ULN at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
- •2. Estimated glomerular filtration rate (eGFR) according to CKD-EPI formula <30 mL/min at Visit 1. (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
- •3. An absolute blood neutrophil count <1,000/mm^3 at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
- •4. Any findings in the medical examination and/or laboratory value assessed at Visit 1 (or at the last safety assessment in the parent trial, concerning the lab tests, if no more than 6 weeks passed since then)., that in the opinion of the investigator may put the patient at risk by participating in the trial.
- •5. A new diagnosis of
- •. Hypogammaglobulinemia
- •. Common variable immunodeficiency
- •. a1-antitrypsin deficiency being treated augmentation therapy
- •. Allergic bronchopulmonary aspergillosis being treated or requiring treatment
- •. Tuberculosis or non-tuberculous mycobacterial infection being treated or requiring treatment according to local guidelines
- •. Palmoplantar keratosis, or keratoderma climactericum
- •. Hypothyroidism, myxedema, chronic lymphedema with associated hyperkeratosis of the skin, acrocyanosis. If a subject has hypothyroidism but is treated and compensated, the subject is allowed into the trial
- •. Psoriasis affecting palms and soles, or body surface area for psoriasis> =10%
- •. Reactive arthritis (Reiters syndrome); keratoderma blennorrhagicum
- •. Pityriasis rubra pilaris
- •. Atopic dermatitis affecting palms and soles; or body surface area for atopic dermatitis> =10%
- •. Active extensive verruca vulgaris, as per investigators discretion
- •. Active fungal infection of hand and/or feet not adequately treated and responsive to antifungal therapy, as per investigators discretion
- •6. Any clinically relevant respiratory infection within 4 weeks prior Visit 2
- •7. Any acute infection requiring systemic or inhaled anti-infective therapy within 4 weeks prior Visit 2
- •8. Positive serological tests for hepatitis B, hepatitis C (also confirmed with HCV RNA), or human immunodeficiency virus (HIV) infection, or known infection status at Visit 2. (The test results will be available after randomisation. In case the results no longer satisfy the entry criteria, these patients will be discontinued.)
- •9. Any new evidence of a concomitant disease, such as PLS, relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal disorders, or patients who are immunocompromised with a higher risk of invasive pneumococcal disease or other invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis), that in the opinion of the investigator, may put the patient at risk by participating in the trial
- •10. Received any live attenuated vaccine within 4 weeks prior to Visit 1
- •Further exclusion criteria apply
研究者
相似试验
招募中
1 期
Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this medicineBronchiectasisMedDRA version: 21.0Level: PTClassification code: 10006445Term: Bronchiectasis Class: 100000004855CTIS2023-503290-38-00Boehringer Ingelheim International GmbH223
招募中
2 期
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin Compared to Each Monotherapy, in Adult Patients With NASH and Liver FibrosisCTRI/2020/08/027184ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 20.0Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000021126MedDRA version: 20.0Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000021126MedDRA version: 20.0Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000021126EUCTR2016-002855-48-BEBayer AG996
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 19.1 Level: LLT Classification code 10046784 Term: Uterine fibroids System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10016628 Term: Fibroids System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10022794 Term: Intramural leiomyoma of uterus System Organ Class: 100000004864EUCTR2016-002855-48-ESBayer AG996
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 19.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000004864EUCTR2016-002855-48-HUBayer AG996